Loading data for ABSI — first visit, this takes a few seconds.
Absci Corporation
8.21 -0.03 (-0.36%)
- Market Cap
- $1.38B
- Volume
- 1.97M
- Dividend yield
- n/a
- Next earnings date
- Nov 16, 2026
Absci Corporation (ABSI) Stock Price, Analysis & Data
Intrinsic Value
Analyst Forecast
Stock Forecasts →Latest Earnings
| Reported | Vs estimate | YoY Change | |
|---|---|---|---|
| Revenue | $318.0K | n/a | -46.37% |
| EPS | -$0.21 | -$0.01 | +12.50% |
Metrics
- Bid
- 6.15
- Market Cap
- 1.38B
- Revenue (ttm)
- 1.56M
- Net Income (ttm)
- -121M
- 2.44
- -0.79
- n/a
- -11.95
- P/B (ttm)
- 5.62
- P/S (ttm)
- 887.20
- Earnings Date
- Nov 16, 2026
- Ask
- 10.44
- Volume
- 1,965,338
- Avg. Volume (20D)
- 4,582,240
- Open
- 8.39
- Previous Close
- 8.24
- Day's Range
- 8.11 - 8.57
- 52-Week Range
- 2.24 - 12.05
- Analyst
- n/a
- Price Target
- n/a
- Dividends
- n/a
- Ex-Dividend Date
- n/a
About Absci Corporation
View profile →Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.
Industry Biotechnology
Sector Healthcare
IPO Date Jul 22, 2021
Employees 140
Stock Exchange NasdaqGS
Ticker Symbol ABSI
Website https://www.absci.com